Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 3 1Phase 2 1

Status

Recruiting 3Completed 3Active not recruiting 3Unknown 2Withdrawn 1Terminated 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Prostatic Neoplasms 5Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 3Triple Negative Breast Neoplasms 2Colonic Neoplasms 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Ureteral Neoplasms 1Tooth, Impacted 1Testicular Neoplasms 1Smoldering Multiple Myeloma 1Oropharyngeal Neoplasms 1Neuroblastoma 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Melanoma 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Hepatoblastoma 1Hematologic Neoplasms 1Hemangioma, Cavernous, Central Nervous System 1Hemangioma, Cavernous 1Ganglioneuroblastoma 1Fibrolamellar hepatocellular carcinoma 1Esophageal Neoplasms 1Epstein-Barr Virus Infections 1Carcinoma, Renal Cell 1Breast Carcinoma In Situ 1Anus Neoplasms 1Anal Canal Carcinoma 1

Interventions

Paclitaxel 62Letrozole 55Fulvestrant 55Trastuzumab 50palbociclib 41pembrolizumab 37Cyclophosphamide 37Carboplatin 37Anastrozole 37pertuzumab 35exemestane 25Tamoxifen 24Capecitabine 24ribociclib 23abemaciclib 23Radiotherapy 21Docetaxel 21olaparib 20Doxorubicin 20Magnetic Resonance Spectroscopy 19trastuzumab deruxtecan 17Surveys and Questionnaires 17durvalumab 16Epirubicin 16Specimen Handling 14Exercise 14130-nm albumin-bound paclitaxel 14Taxes 13Alpelisib 13Goserelin 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × Breast Neoplasms × Watchful Waiting × Clear all
NCT02954874 2026-06-03

Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
1,155 enrolled
Breast

Breast Carcinoma In Situ, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05333874 2026-02-09

CIPHER Study: Pilot Study to Study the Role of ctDNA in Triple Negative and HER2 Positive Early Stage

Rutgers, The State University of New Jersey

Phase EARLY_PHASE1 Active not recruiting
34 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT00080756 2024-08-28

Deslorelin Combined With Low-Dose Add-Back Estradiol and Testosterone in Preventing Breast Cancer in Premenopausal Women Who Are at High Risk for This Disease

City of Hope Medical Center

Phase 2 Active not recruiting
11 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡